Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;14(2):334-340.
doi: 10.21037/tlcr-24-907. Epub 2025 Feb 27.

Sunvozertinib: shining light on lung cancer's exon 20 fight

Tetsuya Mitsudomi  1   2
Affiliations
Editorial

Sunvozertinib: shining light on lung cancer's exon 20 fight

Tetsuya Mitsudomi. Transl Lung Cancer Res. .
No abstract available

Keywords: Non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR); exon 20 insertion mutation; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-907/coif). T.M. has received research funding from Boehringer Ingelheim, AstraZeneca, Taiho, Ono Pharmaceuticals, Merck Sharp & Dohme, Eli Lilly, Chugai Pharmaceuticals, and Bridge Biopharma. Additionally, he has received lecture fees from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Merck Biopharma, Ono Pharmaceuticals, Amgen, and Daiichi-Sankyo. He also participated in advisory board of Regeneron, Bristol Myers Squibb, Janssen and Taiho. The author has no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Structures of EGFR-TKIs developed for Ex20ins are compared with osimertinib. Poziotinib features an anilino-quinazoline moiety with an acrylamide group, similar to second-generation EGFR-TKIs such as afatinib and dacomitinib. Other drugs contain a pyrimidine ring and an acrylamide group. Made at MolView website (https://molview.org/). EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors.
See this image and copyright information in PMC

Comment on

References

    1. Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 2021;597:732-7. 10.1038/s41586-021-03898-1 - DOI - PMC - PubMed
    1. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203. 10.1158/1078-0432.CCR-04-1245 - DOI - PubMed
    1. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23. 10.1158/0008-5472.CAN-04-2818 - DOI - PubMed
    1. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013;12:220-9. 10.1158/1535-7163.MCT-12-0620 - DOI - PMC - PubMed
    1. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol 2018;13:1560-8. 10.1016/j.jtho.2018.06.019 - DOI - PMC - PubMed

LinkOut - more resources